Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors

    Cancer Categories
    • Brain and Nervous System,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck
    Karmanos Trial ID
    • 2023-083
    NCT ID
    • NCT06036121
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    Primary Objectives:

    • To characterize the safety and tolerability of ADRX-0706 in subjects with advanced solid tumors
    • To determine the optimal dose of ADRX-0706

    Secondary Objectives:

    • To determine the maximum tolerated dose (MTD) of ADRX-0706
    • To characterize the pharmacokinetic (PK) profile of ADRX-0706
    • To assess the preliminary anti-tumor activity of ADRX-0706 in subjects with advanced solid tumors
    • To retrospectively assess tumor Nectin-4 expression
    • To assess the incidence of anti-drug antibodies (ADA) to ADRX-0706
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions